Spero Therapeutics (SPRO) EBIT (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of EBIT data on file, last reported at -$7.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 48.83% year-over-year to -$7.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (up 117.37% YoY), and the FY2025 full-year result was $6.3 million, up 108.61% from the prior year.
• EBIT for Q1 2026 stood at -$7.5 million, down from $31.4 million in the prior quarter.
• Across five years, EBIT topped out at $54.5 million in Q4 2023 and bottomed at -$30.2 million in Q1 2022.
• The 5-year median for EBIT is -$12.9 million (2023), against an average of -$5.5 million.
• The widest annual swing landed in 2024, when EBIT tumbled 861.38%; it then jumped 223.68% in 2025.
• A 5-year view of EBIT shows it stood at $26.8 million in 2022, then surged by 103.41% to $54.5 million in 2023, then sank by 146.63% to -$25.4 million in 2024, then surged by 223.68% to $31.4 million in 2025, then sank by 124.0% to -$7.5 million in 2026.
• The last three EBIT figures came in at -$7.5 million (Q1 2026), $31.4 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.

Peer Comparison